PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2873230

| SUBMISSION TYPE: | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|---------------------|----------------|
| DAVID EDWARD WATSON | 01/20/2012 |
| ROBERT W. SIEGEL | 01/20/2012 |
| NAN JIA | 01/24/2012 |
| JOHN HARRISON SLOAN | 01/20/2012 |

RECEIVING PARTY DATA

| Name: | Eli Lilly and Company |
|-------------------|------------------------|
| Street Address: | Lilly Corporate Center |
| Internal Address: | Patent Division |
| City: | Indianapolis |
| State/Country: | INDIANA |
| Postal Code: | 46285 |

PROPERTY NUMBERS Total: 1

| Property Type | Number |
|---------------------|----------|
| Application Number: | 14361017 |

CORRESPONDENCE DATA

Fax Number: (317)276-3861

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: patents@lilly.com

Correspondent Name: ELI LILLY AND COMPANY

Address Line 1: P. O. BOX 6288
Address Line 2: PATENT DIVISION

Address Line 4: INDIANAPOLIS, INDIANA 46206-6288

| ATTORNEY DOCKET NUMBER: | X18677 |
|-------------------------|-------------------|
| NAME OF SUBMITTER: | LINDA M. DURBIN |
| SIGNATURE: | /Linda M. Durbin/ |
| DATE SIGNED: | 05/28/2014 |

Total Attachments: 4

source=X18677Assignment1#page1.tif source=X18677Assignment1#page2.tif

source=X18677Assignment2#page1.tif source=X18677Assignment2#page2.tif

ASSIGNMENT

WHEREAS.

David Edward Watson of Indianapolis, IN

Citizenship: US

Robert W. Siegel of Fountaintown, IN

Citizenship: US

Nan Jia of West Labanon, NH

Citizenship: US

John Harrison Sloan of Zionsville, IN

Citizenship: US

are co-inventors (with the persons listed above) of an invention that is the subject of a patent application ("Application") which is entitled ANTI-GLUCAGON ANTIBODIES AND USES THEREOF, for filing:

| in the United States Patent and Tra accorded Serial Number 61/566,080, | demark Office on December 2, 2011 and |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| in theand accorded Serial Number | |
| in the Spanish Patent Office as a Eand accorded Serial Number | propean Application on |
| with United States Patent and Tra | er the Patent Cooperation Treaty ("PCT"). demark Office acting as Receiving Office rded Serial Number |
| with The State Intellectual Prop | er the Patent Cooperation Treaty ("PCT"). berty Office (SIPO) of China acting asand accorded Serial Number |
| both of which claim the benefit of prio | |

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial numbers and filing dates for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation baving its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns

Page 2 of 2 Docket No. P-18677

(collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lifly or its nominees, in the United States and in all other countries where Lifty may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

| 20 Jan 2012 | DAGWAL | |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date | David Edward Watson | |
| 20 Ja 2012 | The Commence of the Commence o | (Comment |
| Date | Bobert W. Siegel | and the state of t |
| Date | Nan Jia | |
| 20 Day 12 | Jel-Harrise | 9-560a- |
| Date | Jobn Harrison Stoan | |

ASSIGNMENT

WHEREAS,

David Edward Watson of Indianapolis, IN Citizenship: US

Robert W. Siegel of Fountaintown, IN Citizenship: US

Nan Jia of West Labanon, NH

Citizenship: US

John Harrison Sloan of Zionsville, IN

Citizenship: US

are co-inventors (with the persons listed above) of an invention that is the subject of a patent application ("Application") which is entitled ANTI-GLUCAGON ANTIBODIES AND USES THEREOF, for filing:

| in the United States Patent and Tra- accorded Serial Number 61/566,080, | demark Office on December 2, 2011 and |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| in the and accorded Serial Number | 08 |
| in the Spanish Patent Office as a Ed and accorded Serial Number | propean Application on |
| as an international application und with United States Patent and Tra | ier the Patent Cooperation Treaty ("PCT") demark Office acting as Receiving Office rded Scrial Number, |
| with The State Intellectual Prop | er the Patent Cooperation Treaty ("PCT") perty Office (SIPO) of China acting as and accorded Serial Number |
| both of which claim the benefit of prior, filed | |

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial numbers and filing dates for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns

(collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT. United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

| Date | David Edward Watson |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date | Robert W. Siegel |
| 01/24/2012 | and the second s |
| Date | Nan Jia |
| Date | John Harrison Sloan |